Migraine affects around 600,000 people in Scotland, and over 35,000 were admitted to hospital with it in 2020. Working with AbbVie's PR agency, we took news of a new treatment option to broadcasters: the Scottish Medicines Consortium had accepted AbbVie's migraine treatment AQUIPTA (atogepant) for restricted use on NHS Scotland, the first body to accept it on the NHS. The chief executive of the Migraine Trust went on air in radio and TV interviews, explaining what timely access to a new treatment could mean for eligible people living with migraine. The campaign secured 5 items of radio and TV coverage reaching 2.5 million people, including That's TV Scotland and Sky News Radio.
AbbVie wanted to reach UK and Scottish audiences with news of a new NHS Scotland treatment option for migraine.
The message
The SMC is the first to accept atogepant on the NHS, giving eligible people living with migraine in Scotland timely access to a new treatment option with the potential to improve their lives.
The angle
The Scottish Medicines Consortium accepted AbbVie's migraine treatment AQUIPTA (atogepant) for restricted use on NHS Scotland, the first body to accept it on the NHS. Migraine affects around 600,000 people in Scotland, and over 35,000 were admitted to hospital with it in 2020.
On air
The chief executive of the Migraine Trust
The result
5 items of coverage reaching 2.5 million, including Sky News Radio, That's TV Scotland.
Planning a broadcast PR campaign?
Talk to the team about radio and TV interviews for your brand, or for your clients if you run a PR agency.
